AVANIR PHARMACEUTICALS, INC. 4
4 · AVANIR PHARMACEUTICALS, INC. · Filed Dec 18, 2014
Insider Transaction Report
Form 4
OCAMPO CHRISTINE
Vice President, Finance
Transactions
- Exercise/Conversion
Common Stock
2014-12-16$2.59/sh+12,500$32,375→ 127,077 total - Sale
Common Stock
2014-12-18$16.93/sh−5,780$97,855→ 108,797 total - Sale
Common Stock
2014-12-16$16.94/sh−12,500$211,750→ 132,077 total - Exercise/Conversion
Common Stock
2014-12-16$4.18/sh+17,500$73,150→ 144,577 total - Exercise/Conversion
Stock Option (Right to Buy)
2014-12-16−12,500→ 17,500 totalExercise: $2.59Exp: 2022-12-17→ Common Stock (12,500 underlying) - Sale
Common Stock
2014-12-16$16.94/sh−17,500$296,450→ 114,577 total - Exercise/Conversion
Stock Option (Right to Buy)
2014-12-16−17,500→ 0 totalExercise: $4.18Exp: 2020-12-01→ Common Stock (17,500 underlying)
Footnotes (6)
- [F1]Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
- [F2]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. A majority of the proceeds from the sales will be used to pay required withholdings due by the Reporting Person for vesting RSUs.
- [F3]Represents the weighted-average price at which shares were sold within a range between $16.92 and $16.95. The reporting persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]Represents the weighted-average price at which shares were sold within a range between $16.93 and $16.95. The reporting persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]The option was granted on 12/17/2012 and vested with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares quarterly thereafter over the next three years.
- [F6]The option was granted on 12/1/2010 and vested with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares quarterly thereafter over the next three years.